Print Friendly

Summary of the Endocrine Society Clinical Guideline on the Treatment of Cushing’s Syndrome: Part 2

A previous issue of this newsletter covered the first line treatment options for Cushing’s disease and Cushing’s syndrome as outlined in the recently published Endocrine Society guidelines. This summary will discuss the options for treatment in cases of recurrent or persistent Cushing’s disease or in patients where surgery is not an option. Cushing’s Disease ReportedContinue Reading

An Update on Medications Used to Treat Cushing’s

For the majority of individuals with Cushing’s syndrome (CS), surgery directed at the pituitary or adrenal glands is the first and most important treatment; however, many patients do not have a sustained remission after surgery. As a result, treatment options other than surgery are needed for many patients with CS. Until recently, the use ofContinue Reading

Mifepristone (Korlym): First FDA-Approved Medication for the Treatment of Cushing’s Syndrome

On February 17, 2012, the Food and Drug Administration (FDA) approved mifepristone (Korlym) as a once daily oral medication to treat patients with Cushing’s syndrome. The specific indication was for the treatment of elevated blood sugar in patients with Cushing’s syndrome and type 2 diabetes mellitus. Mifepristone was approved for patients who had failed orContinue Reading

Medical Therapy for Cushing’s Disease: Spotlight on the Investigational Medication SOM230 (Pasireotide)

Cortisol is a hormone (chemical messenger) made in the adrenals, which are small, triangular shaped glands located on top of the kidneys. The production of cortisol is controlled by hormonal signals from the hypothalamus and the pituitary gland, both of which are in the head. The pituitary hormone, called adrenocorticotropic hormone (ACTH), is made inContinue Reading